Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/mds.28293 http://scihub22266oqcxt.onion/10.1002/mds.28293 32860226!ä!32860226 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mov+Disord 2020 ; 35 (12): 2129-2133 Nephropedia Template TP {{tp|p=32860226|t=2020. The Impact of COVID-19 on Access to Parkinson s Disease Medication |pdf=|usr=}}{{32860226}} gab.com Text The Impact of COVID-19 on Access to Parkinson s Disease Medication JO: Mov Disord http://www.kidney.de/pget.php?&tw=1&pmid=32860226 #FOAvip BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. (c) 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Twit Text FOAVip The Impact of COVID-19 on Access to Parkinson s Disease Medication ????Mov Disord http://www.kidney.de/pget.php?&tw=1&pmid=32860226 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32860226 #FOAvip English Wikipedia <ref>{{Cite pmid|32860226}}</ref> The Impact of COVID-19 on Access to Parkinson s Disease Medication #MMPMID32860226 Cheong JL; Goh ZHK; Marras C; Tanner CM; Kasten M; Noyce AJ Mov Disord 2020[Dec]; 35 (12): 2129-2133 PMID32860226show ga BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. (c) 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |COVID-19/*complications/virology[MESH] |Disabled Persons/psychology[MESH] |Humans[MESH] |Parkinson Disease/*drug therapy/*epidemiology[MESH] |SARS-CoV-2/*pathogenicity[MESH]The Impact of COVID-19 on Access to Parkinson s Disease Medication (epmc).pdf DeepDyve Pubget Overpricing